The FDA is reportedly mulling over a decision that would slap a black box warning on COVID-19 vaccines—the kind of big, bold safety alert that appears at the top of a drug's label when things could go seriously wrong. It's the agency's most severe warning, and right now, it's drawing plenty of criticism from experts who say the data doesn't back it up.
This latest move represents another chapter in the Trump administration's ongoing reexamination of COVID-19 vaccines, products that were widely celebrated as a signature achievement during President Donald Trump's first term. Now, members of his health team are taking a second look.
To understand what we're talking about here, black box warnings are reserved for the most serious risks. They're hard to miss—literally boxed in black at the top of prescribing information. Think opioids, where the warning screams about addiction, overdose, and death. Or Accutane, the acne medication that comes with stark warnings about severe birth defects during pregnancy. The smallpox and mpox vaccine ACAM2000 carries similar warnings for risks including myocarditis and encephalitis.
Who's Behind the Proposal?
According to CNN, citing people familiar with the discussions, the push is being driven by Dr. Vinay Prasad, who serves as the FDA's chief medical and scientific officer and heads its Center for Biologics Evaluation and Research. But here's the thing—the proposal isn't set in stone yet. Sources say it's still being hammered out and could change.
The Big Unknowns
Plenty of questions remain unanswered. Would this warning apply across the board to all COVID-19 vaccines, or would it target only the mRNA-based shots that have become a focal point of the administration's review? Right now, three COVID-19 vaccines have full FDA approval in the United States. Two of them—developed by Pfizer Inc. (PFE) and its partner BioNTech SE (BNTX), along with Moderna Inc. (MRNA)—use mRNA technology that's been under particularly close scrutiny.
The timing is murky too. While reports suggest something could be announced by year-end, it's unclear exactly when or how broad these warnings might be. Would they apply to every age group, or would there be distinctions based on who's getting the shot?
Andrew Nixon, a spokesperson for the U.S. Department of Health and Human Services, pushed back on the speculation Thursday, telling CNN that any claims about pending FDA actions are "pure speculation" unless the agency makes an official announcement.
The debate raises a fundamental question: what does the evidence actually show? Outside experts are already speaking up, arguing that the scientific data doesn't support such a dramatic regulatory move. Black box warnings aren't handed out lightly—they're meant to signal clear, serious risks that outweigh benefits in certain contexts. Whether COVID-19 vaccines meet that threshold is now at the center of an increasingly heated discussion.
